These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38636191)

  • 1. Development and validation of ELISA method for quantification of Q-1802 in serum and its application to pharmacokinetic study in ICR Mouse.
    Meng Q; Hao Y; Yang M; Du Y; Wang S
    J Pharm Biomed Anal; 2024 Aug; 245():116138. PubMed ID: 38636191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of an enzyme-linked immunosorbent assay for the quantification of a recombinant humanized anti-IL-4Rα monoclonal antibody CM310 in serum and its application to pharmacokinetic study in Sprague-Dawley Rats.
    Hao Y; Zhang L; Meng Q; Jia Q; Ma J; Zhang X
    Anal Biochem; 2024 Nov; 694():115623. PubMed ID: 39059567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum.
    Idowu OS; Craigen JL; Veal GJ; Jamieson D
    Bioanalysis; 2022 Sep; 14(18):1241-1249. PubMed ID: 36378607
    [No Abstract]   [Full Text] [Related]  

  • 4. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity.
    Huang PL; Kan HT; Hsu CH; Hsieh HT; Cheng WC; Huang RY; You JJ
    J Transl Med; 2023 May; 21(1):346. PubMed ID: 37226226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
    Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
    Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered mRNA-expressed bispecific antibody prevent intestinal cancer via lipid nanoparticle delivery.
    Wu L; Wang W; Tian J; Qi C; Cai Z; Yan W; Xuan S; Shang A
    Bioengineered; 2021 Dec; 12(2):12383-12393. PubMed ID: 34895063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a novel semi-homogenous clinical assay for quantitation of Ranibizumab in human serum.
    Lowe J; Wakshull E; Shek T; Chuntharapai A; Elliott R; Rusit J; Maia M
    J Immunol Methods; 2018 Oct; 461():44-52. PubMed ID: 29772250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
    Lakins MA; Koers A; Giambalvo R; Munoz-Olaya J; Hughes R; Goodman E; Marshall S; Wollerton F; Batey S; Gliddon D; Tuna M; Brewis N
    Clin Cancer Res; 2020 Aug; 26(15):4154-4167. PubMed ID: 32345647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Pharmacokinetic Assessment of the FIC CLDN18.2/4-1BB Bispecific Antibody in Rhesus Monkeys.
    Wang J; Dong T; Gong X; Li D; Sun J; Luo Y; Wu H
    Int J Toxicol; 2024; 43(3):291-300. PubMed ID: 38115178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
    Kotanides H; Li Y; Malabunga M; Carpenito C; Eastman SW; Shen Y; Wang G; Inigo I; Surguladze D; Pennello AL; Persaud K; Hindi S; Topper M; Chen X; Zhang Y; Bulaon DK; Bailey T; Lao Y; Han B; Torgerson S; Chin D; Sonyi A; Haidar JN; Novosiadly RD; Moxham CM; Plowman GD; Ludwig DL; Kalos M
    Cancer Immunol Res; 2020 Oct; 8(10):1300-1310. PubMed ID: 32873605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
    Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
    Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme-linked immunosorbent assays for quantification of MMAE-conjugated ADCs and total antibodies in cynomolgus monkey sera.
    Pei M; Liu T; Ouyang L; Sun J; Deng X; Sun X; Wu W; Huang P; Chen YL; Tan X; Liu X; Zhu P; Liu Y; Wang D; Wu J; Wang Q; Wang G; Gong L; Qin Q; Wang C
    J Pharm Anal; 2022 Aug; 12(4):645-652. PubMed ID: 36105165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.
    Jiang H; Ni H; Zhang P; Guo X; Wu M; Shen H; Wang J; Wu W; Wu Z; Ding J; Tang R; Zhou S; Chen B; Yu M; Jing H; Liu J
    Oncoimmunology; 2021; 10(1):1943180. PubMed ID: 34239776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity.
    Kraman M; Faroudi M; Allen NL; Kmiecik K; Gliddon D; Seal C; Koers A; Wydro MM; Batey S; Winnewisser J; Young L; Tuna M; Doody J; Morrow M; Brewis N
    Clin Cancer Res; 2020 Jul; 26(13):3333-3344. PubMed ID: 32299814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
    Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X
    Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962
    [No Abstract]   [Full Text] [Related]  

  • 16. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models.
    Kurino T; Matsuda R; Terui A; Suzuki H; Kokubo T; Uehara T; Arano Y; Hisaka A; Hatakeyama H
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32041818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities.
    Li HY; Chen YL; Deng XN; Li HH; Tan J; Liu GJ; Zheng YJ; Pei M; Peng KT; Yue LL; Chen XJ; Liu Y; Zhao YS; Wang CH
    Acta Pharmacol Sin; 2023 Nov; 44(11):2322-2330. PubMed ID: 37328649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of an enzyme-linked immunosorbent assay for the quantification of gelonin in mouse plasma.
    Engler FA; Balthasar JP
    J Immunoassay Immunochem; 2016; 37(6):611-22. PubMed ID: 27135787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid.
    Pluim D; Ros W; van Bussel MTJ; Brandsma D; Beijnen JH; Schellens JHM
    J Pharm Biomed Anal; 2019 Feb; 164():128-134. PubMed ID: 30368118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.